Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Jun 01, 2023 11:53am
109 Views
Post# 35475030

RE:RE:next steps?

RE:RE:next steps?Guess we can all hope for the  best.  This decision  will likely end any delay this  many month lead up  to the arbitration has caused.  Hpwever  ,  usually  , the  market precedes  announcements.  In this cae given the trading, it would appear that no one thinks  the outcome will mean any real short term gain for Replicel.  If things continue as they were  , it could still take years to reach market with a successful product.

If  'the market'  felt anything really meaningful will come out of this arbitration  would the  stock not now be trading   at  $1  to $3  right  now??

Hope I am wrong  but cannot see any real way the  share price goes up no matter which way the decision goes??   Sure no one is selling  in anticipation of a 'good' outcome  , but by a like token  , does not look like anyone is buying either.

Only way i see a  quick uptick in the price is if  the Parties are negotiating a deal of sorts  now  - prior to the  decision coming out.   If the insiders decide to get out  , there will be millions of shares hitting the market and we will be down to  0.01  or less

GLTA
<< Previous
Bullboard Posts
Next >>